Zdrowie i gospodarka · 13/01/2017

FDA Releases Draft Guidance on 180-Day Exclusivity for Generic Drug Products

The FDA has announced the availability of a draft guidance for industry addressing questions about the 180-day exclusivity provisions of the FD&C Act, aiming to enhance transparency and facilitate the development of generic drug products.